BeStock  
Stocks › Medical Devices › TMDX

TransMedics TMDX

US equityMarket cap rank #2438Medical Devices
$85.25 −$8.77 (-9.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $85.60 +0.41%
Open$90.81
Prev close$94.02
Day range$83.89 – $91.62
Volume1.59M
Market cap$2.96B
P/E (TTM)23.2
Dividend yield–

Earnings

Average move on report day±17.2%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+51.2%
Worst reaction-29.9%

Stock move on the day after each report

+51.2%2023/Q3+14.1%2023/Q4+24.9%2024/Q1-29.9%2024/Q3+5.8%2024/Q4+19.6%2025/Q1+10.5%2025/Q2+1.1%2025/Q3-4.3%2025/Q4-23.2%2026/Q1-5.3%2026/Q2+27.9%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q35 Nov 2026After Market±18.0%+27.92%Bigger than priced
2026/Q24 Aug 2026After Market±15.6%-5.28%Within range
2026/Q15 May 2026After Market±12.9%-23.19%Bigger than priced
2025/Q424 Feb 2026After Market±16.0%-4.30%Within range
2025/Q329 Oct 2025After Market±17.5%+1.09%Within range
2025/Q230 Jul 2025After Market±19.0%+10.46%Within range
2025/Q18 May 2025After Market±19.3%+19.64%Bigger than priced
2024/Q427 Feb 2025After Market±27.3%+5.82%Within range
2024/Q328 Oct 2024After Market±24.8%-29.90%Bigger than priced
2024/Q130 Apr 2024After Market±18.7%+24.93%Bigger than priced
2023/Q426 Feb 2024After Market±27.5%+14.11%Within range
2023/Q36 Nov 2023After Market±20.8%+51.18%Bigger than priced
2023/Q23 Aug 2023After Market±16.8%-8.31%Within range
2023/Q11 May 2023After Market±14.5%-5.18%Within range
2022/Q422 Feb 2023After Market±17.5%+20.55%Bigger than priced
2022/Q33 Nov 2022After Market±23.6%+24.00%Bigger than priced

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Liver revenue$150.44M 74.1%
  • Heart revenue$38.60M 19.0%
  • Service revenue unrelated to Organ Care System (OCS) transplant$10.50M 5.2%
  • Lung revenue$3.08M 1.5%
  • Other transplant-related revenue$437,000.00 0.2%

Latest reported quarter: Q3, ended Sep 2026

Revenue$203.01M+41.1% YoY
Operating profit$28.14M+20.8% YoY
Net profit$17.07M-29.8% YoY
Diluted EPS$0.46-30.3% YoY
Free cash flow$27.60M-55.4% YoY
Operating cash flow$36.00M

Revenue, last 8 quarters

$121.6MDec '24$143.5MMar '25$157.4MJun '25$143.8MSep '25$160.8MDec '25$173.9MMar '26$189.9MJun '26$203.0MSep '26

Net profit, last 8 quarters

$6.9MDec '24$25.7MMar '25$34.9MJun '25$24.3MSep '25$105.4MDec '25$7.3MMar '26$14.7MJun '26$17.1MSep '26

Profitability & balance sheet

Gross margin58.6%
Operating margin11.9%
Net margin19.9%
Return on equity31.9%
Return on assets11.7%
Return on invested capital13.9%
Current ratio4.53
Liabilities / assets63.7%
Cash & investments$492.96M
Total debt$863.26M
Net cash (debt)-$370.30M
Free cash flow / sales6.1%

Discussion

No comments yet — be the first to weigh in on TMDX.

Sign in to join the discussion.

Scroll to Top